LipoMedix, a clinical-stage, oncology-focused pharmaceutical company involved in the development of cancer therapy based on a pegylated liposomal drug delivery platform, said that its lead compound, Promitil (PL-MLP), will be manufactured in the U.S. by ForDoz Pharma, a specialty pharmaceutical company focused on the development, manufacturing, and commercialization of value-added sterile and complex injectable products.    Promitil’s formulation is designed for selective delivery of the therape...